Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Skin Lesion Classification Using Convolutional Neural Network With Novel Regularizer
279
Zitationen
1
Autoren
2019
Jahr
Abstract
One of the most common types of human malignancies is skin cancer, which is chiefly diagnosed visually, initiating with a clinical screening followed by dermoscopic analysis, histopathological assessment, and a biopsy. Due to the fine-grained differences in the appearance of skin lesions, automated classification is quite challenging through images. To attain highly segregated and potentially general tasks against the finely grained object categorized, deep convolutional neural networks (CNNs) are used. In this paper, we propose a new prediction model that classifies skin lesions into benign or malignant lesions based on a novel regularizer technique. Hence, this is a binary classifier that discriminates between benign or malignant lesions. The proposed model achieved an average accuracy of 97.49%, which in turns showed its superiority over other state-of-the-art methods. The performance of CNN in terms of AUC-ROC with an embedded novel regularizer is tested on multiple use cases. The area under the curve (AUC) achieved for nevus against melanoma lesion, seborrheic keratosis versus basal cell carcinoma lesion, seborrheic keratosis versus melanoma lesion, solar lentigo versus melanoma lesion is 0.77, 0.93, 0.85, and 0.86, respectively. Our results showed that the proposed learning model outperformed the existing algorithm and can be used to assist medical practitioners in classifying various skin lesions.
Ähnliche Arbeiten
Dermatologist-level classification of skin cancer with deep neural networks
2017 · 13.468 Zit.
Tumor Angiogenesis: Therapeutic Implications
1971 · 10.111 Zit.
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
2011 · 7.670 Zit.
Pembrolizumab versus Ipilimumab in Advanced Melanoma
2015 · 5.808 Zit.
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
2017 · 5.360 Zit.